BioStratum Leases Newest Park Building Research

Triangle Park, N.C. -- August 24, 2000 --
BioStratum Incorporated signed a seven-year lease with
a three-year extension option for Highwoods Properties' newest addition to Creekstone Park. The lease commitment for the 35,000+ square foot Maplewood Building in the Research Triangle Park area underscores the biotechnology company's commitment to continue to grow and prosper here.

"We are consolidating our headquarters and laboratory operations in the new building in April and look forward
to a long association with both the Research Triangle community and Highwoods", said Dr. Claus Kühl,
President and CEO of BioStratum. He added "Highwoods has produced a first class facility to meet our needs as
a growing company and we are very excited at the opportunity to bring our team together in one location."

The new BioStratum facility was designed by HagerSmith Design and Flad & Associates and is being constructed by Clancy & Theys. Expected completion date is April 1, 2001.

BioStratum Incorporated is the world leader in research and development related to the basal lamina, a thin membrane in human tissue that functions as a "biological operating system," directing the behavior of cells and tissue in both health and disease. Two decades of innovative research
by BioStratum scientists have resulted in the identification of drug candidates for diabetic kidney disease and cancer as well as a number of novel therapeutic approaches for autoimmune disease and regenerative medicine. The Company's lead drug candidate, Pyridorin™, is currently advancing in clinical trials for diabetic kidney disease. Angiocol™, its proprietary anti-angiogenesis agent,
has completed preclinical studies and will soon begin clinical testing.